Does NLRP3/IL-1β pathway inhibition prevent septic cardiomyopathy?
Inhibition of the NLRP3/IL-1β pathway may be a useful strategy to prevent sepsis-induced cardiomyopathy by attenuating cardiac atrophy and contractile impairment.
IL-1β causes atrophy, impairs contractility and relaxation and decreases deformation of cardiomyocytes. Because NLRP3/IL-1β pathway inhibition attenuates cardiac atrophy and cardiomyopathy in sepsis, it could be useful to prevent septic cardiomyopathy.
Büsch et al. (Thu,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: